Natera Nets $19M Verdict In Cancer Test Patent Case
A Delaware federal jury on Monday found that a unit of genetic testing company Invitae owes about $19.35 million for directly infringing three Natera patents covering cancer testing technology....To view the full article, register now.
Already a subscriber? Click here to view full article